Evidence map›Paper›PMID 38212449›Full record

ArticleArchives of toxicology2024

TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2

Xinyi Shao, Dawei Yang, Liuqun Shan, Xueqin Yan, Di Xu, Lei Li, Yidan Sun, Qiang Yu, Honglei Zhou, Yongbin Ding and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xinyi Shao *The First Clinical College, Nanjing University of Chinese Medicine, Nanjing, China.
Dawei Yang *Department of Pharmacy, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China. David_young1994@outlook.com.ORCID 0000-0002-5392-1896
Liuqun Shan *Department of General Surgery, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Xueqin YanDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Di XuDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lei LiDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yidan SunDepartment of Laboratory Medicine, Pukou Branch Hospital of Jiangsu Province Hospital (Nanjing Pukou People Hospital), Nanjing, China.
Qiang YuDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Honglei ZhouDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. zhouhonglei@jsph.org.cr.
Yongbin DingDepartment of General Surgery, Jurong Branch Hospital of Jiangsu Province Hospital (Jurong People Hospital), Nanjing Medical University, Zhenjiang, China. njdyb@njmu.edu.cn.
Jinhai TangThe First Clinical College, Nanjing University of Chinese Medicine, Nanjing, China. jhtang@njmu.edu.cn.
Jiangsu Province Hospital · CNNanjing University of Chinese Medicine · CNShenzhen University Health Science Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human epidermal growth factor receptor 2-positive (HER2

Indexed as

Antineoplastic AgentsBreast NeoplasmsNeoplasmsProdrugsAnimalsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibMiceProtein Kinase InhibitorsAntineoplastic AgentsErb-b2 Receptor Tyrosine KinasesLapatinibProdrugsProtein Kinase InhibitorsHER2+ breast cancerHypoxia-targeted strategyTH-4000Tyrosine kinase inhibitor

Identifiers

PMID38212449
OpenAlexW4390754508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.